Hepatitis-A-Virus-Antigen shortage — AU supply status & alternatives

Hepatitis-A-Virus-Antigen

—

In shortage · Australia

Twinrix Junior

In declared shortage · 🇦🇺 Australia & also short in🇨🇦 CA🇧🇪 BE

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)

Brand names	Twinrix Junior

Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Recalls official enforcement reports

🇦🇺

Hepatitis B Immunoglobulin-VF 100IU AUBatch Number: 3640800146Expiry Date: 12-Oct-2026ARTG 61213

CSL Behring Australia Pty Ltd · Oct 2024

Class IIdetails ↗

🌐

Hepacare

Evans Vaccines Ltd. · Oct 2002

Class Unifieddetails ↗

Verified timeline regulator events

🇨🇦 29 June 2026

medium reported

🇧🇪 1 June 2026

medium reported

🇨🇦 20 May 2026

medium reported

🇨🇦 15 May 2026

medium reported

🇨🇦 23 Mar 2026

medium reported

🇨🇦 16 Mar 2026

medium reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.